Hemorheological, hemostatic and metabolic long-term (24 months) study of young women taking a monophasic pill containing gestodene and ethinylestradiol

S. B. Solerte, M. Fioravanti, A. Spinillo, E. Capuzzo, A. Iasci, M. Mastrolilli, P. Berard, P. Reboli, E. Ferrari, S. Guaschino

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: To investigate the hemoreologic, hemostatic and metabolic effects of a monophasic low-dose oral contraceptive. Methods: Twenty healthy young women desiring hormonal contraception were studied before, during and after a 2 year course of a monophasic oral contraceptive containing gestodene 75 μg and ethinylestradiol 30 μg. Twenty-nine matched healthy young women were chosen as the control group. Results: No differences in any of the variables evaluated (body mass index, blood pressure, erythrocyte deformability, concentrations of triglycerides, total HDL, LDL and VLDL cholesterol, non-esterified fatty acids, serum lipoproteins VLDL, LDL, HDL and apolipoproteins A, A1 and B, fibrinogen, fibronectin, von Willebrand factor antigen, α2-macroglobulin, antithrombin III, prolactin) were demonstrated between the women taking the monophasic pill and the control group. Conclusion: Oral contraception with the monophasic gestodene and ethinylestradiol combination may be a safe long-term hormonal contraceptive method for young women and prevent the development of cardiovascular complications.

Original languageEnglish
Pages (from-to)85-91
Number of pages7
JournalItalian Journal of Gynaecology and Obstetrics
Volume5
Issue number3
Publication statusPublished - 1993

Fingerprint

Ethinyl Estradiol
Hemostatics
Contraception
Oral Contraceptives
Erythrocyte Deformability
Apolipoproteins A
VLDL Cholesterol
Macroglobulins
Control Groups
Antithrombin III
VLDL Lipoproteins
Apolipoprotein A-I
von Willebrand Factor
Apolipoproteins B
LDL Lipoproteins
Fibronectins
Prolactin
LDL Cholesterol
Fibrinogen
HDL Cholesterol

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Hemorheological, hemostatic and metabolic long-term (24 months) study of young women taking a monophasic pill containing gestodene and ethinylestradiol. / Solerte, S. B.; Fioravanti, M.; Spinillo, A.; Capuzzo, E.; Iasci, A.; Mastrolilli, M.; Berard, P.; Reboli, P.; Ferrari, E.; Guaschino, S.

In: Italian Journal of Gynaecology and Obstetrics, Vol. 5, No. 3, 1993, p. 85-91.

Research output: Contribution to journalArticle

Solerte, S. B. ; Fioravanti, M. ; Spinillo, A. ; Capuzzo, E. ; Iasci, A. ; Mastrolilli, M. ; Berard, P. ; Reboli, P. ; Ferrari, E. ; Guaschino, S. / Hemorheological, hemostatic and metabolic long-term (24 months) study of young women taking a monophasic pill containing gestodene and ethinylestradiol. In: Italian Journal of Gynaecology and Obstetrics. 1993 ; Vol. 5, No. 3. pp. 85-91.
@article{d4eb026ae50146449a087f305f195f41,
title = "Hemorheological, hemostatic and metabolic long-term (24 months) study of young women taking a monophasic pill containing gestodene and ethinylestradiol",
abstract = "Objective: To investigate the hemoreologic, hemostatic and metabolic effects of a monophasic low-dose oral contraceptive. Methods: Twenty healthy young women desiring hormonal contraception were studied before, during and after a 2 year course of a monophasic oral contraceptive containing gestodene 75 μg and ethinylestradiol 30 μg. Twenty-nine matched healthy young women were chosen as the control group. Results: No differences in any of the variables evaluated (body mass index, blood pressure, erythrocyte deformability, concentrations of triglycerides, total HDL, LDL and VLDL cholesterol, non-esterified fatty acids, serum lipoproteins VLDL, LDL, HDL and apolipoproteins A, A1 and B, fibrinogen, fibronectin, von Willebrand factor antigen, α2-macroglobulin, antithrombin III, prolactin) were demonstrated between the women taking the monophasic pill and the control group. Conclusion: Oral contraception with the monophasic gestodene and ethinylestradiol combination may be a safe long-term hormonal contraceptive method for young women and prevent the development of cardiovascular complications.",
author = "Solerte, {S. B.} and M. Fioravanti and A. Spinillo and E. Capuzzo and A. Iasci and M. Mastrolilli and P. Berard and P. Reboli and E. Ferrari and S. Guaschino",
year = "1993",
language = "English",
volume = "5",
pages = "85--91",
journal = "Italian Journal of Gynaecology and Obstetrics",
issn = "1121-8339",
publisher = "CIC Edizioni Internazionali s.r.l.",
number = "3",

}

TY - JOUR

T1 - Hemorheological, hemostatic and metabolic long-term (24 months) study of young women taking a monophasic pill containing gestodene and ethinylestradiol

AU - Solerte, S. B.

AU - Fioravanti, M.

AU - Spinillo, A.

AU - Capuzzo, E.

AU - Iasci, A.

AU - Mastrolilli, M.

AU - Berard, P.

AU - Reboli, P.

AU - Ferrari, E.

AU - Guaschino, S.

PY - 1993

Y1 - 1993

N2 - Objective: To investigate the hemoreologic, hemostatic and metabolic effects of a monophasic low-dose oral contraceptive. Methods: Twenty healthy young women desiring hormonal contraception were studied before, during and after a 2 year course of a monophasic oral contraceptive containing gestodene 75 μg and ethinylestradiol 30 μg. Twenty-nine matched healthy young women were chosen as the control group. Results: No differences in any of the variables evaluated (body mass index, blood pressure, erythrocyte deformability, concentrations of triglycerides, total HDL, LDL and VLDL cholesterol, non-esterified fatty acids, serum lipoproteins VLDL, LDL, HDL and apolipoproteins A, A1 and B, fibrinogen, fibronectin, von Willebrand factor antigen, α2-macroglobulin, antithrombin III, prolactin) were demonstrated between the women taking the monophasic pill and the control group. Conclusion: Oral contraception with the monophasic gestodene and ethinylestradiol combination may be a safe long-term hormonal contraceptive method for young women and prevent the development of cardiovascular complications.

AB - Objective: To investigate the hemoreologic, hemostatic and metabolic effects of a monophasic low-dose oral contraceptive. Methods: Twenty healthy young women desiring hormonal contraception were studied before, during and after a 2 year course of a monophasic oral contraceptive containing gestodene 75 μg and ethinylestradiol 30 μg. Twenty-nine matched healthy young women were chosen as the control group. Results: No differences in any of the variables evaluated (body mass index, blood pressure, erythrocyte deformability, concentrations of triglycerides, total HDL, LDL and VLDL cholesterol, non-esterified fatty acids, serum lipoproteins VLDL, LDL, HDL and apolipoproteins A, A1 and B, fibrinogen, fibronectin, von Willebrand factor antigen, α2-macroglobulin, antithrombin III, prolactin) were demonstrated between the women taking the monophasic pill and the control group. Conclusion: Oral contraception with the monophasic gestodene and ethinylestradiol combination may be a safe long-term hormonal contraceptive method for young women and prevent the development of cardiovascular complications.

UR - http://www.scopus.com/inward/record.url?scp=0027521650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027521650&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0027521650

VL - 5

SP - 85

EP - 91

JO - Italian Journal of Gynaecology and Obstetrics

JF - Italian Journal of Gynaecology and Obstetrics

SN - 1121-8339

IS - 3

ER -